ArticleNeurology and therapy2026
Clinical Outcomes Among Patients Taking Brexpiprazole as Augmentation with Antidepressant Treatment for Major Depressive Disorder in a United States Real-World Dataset.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEfficacy of brexpiprazole as an adjunctive treatment to antidepressants for the treatment of major depressive disorder (MDD) has been demonstrated in several clinical trials. However, there is limited evidence on longer-term and real-world clinical effectiveness. The primary aim of this study was to characterize and evaluate clinical outcomes among patients with MDD treated with adjunctive brexpiprazole.
methodsThis observational study examined outcomes among patients with MDD treated with brexpiprazole augmentation from a large United States real-world MDD dataset. The index date was the date of the first brexpiprazole prescription (written or filled) between July 10, 2015 and January 31, 2023. Patients with ≥ 2 MDD diagnoses before the index date, treatment with brexpiprazole for ≥ 30 days while on antidepressants; treatment with antidepressants for ≥ 60 days pre- and 30 days post-initiation, and with ≥ 1 9-item Patient Health Questionnaire (PHQ-9) score recorded 12 months pre- and post-index date were included. The primary outcome was improvement in depression symptoms as measured by the PHQ-9, together with PHQ-9 response (≥ 50% decrease in score) and remission (score < 5). Secondary outcomes assessed anxiety and overall clinical improvement.
resultsThere were 1073 patients with MDD included in the final cohort. Mean PHQ-9 score decreased from baseline to follow-up (12.0 vs. 9.2; mean change - 2.8; 95% CI: - 3.1 to - 2.4; p < 0.001). PHQ-9 response was shown in 325 (30.3%) patients. The percentage of patients in PHQ-9 remission increased from baseline to follow-up (11.0% vs. 25.7%; p < 0.001). Anxiety and overall clinical status also improved.
conclusionFindings suggest sustained clinical improvement among patients with MDD when antidepressant treatment was augmented with brexpiprazole. These findings are consistent with other studies of brexpiprazole.
Indexed as
Identifiers
42905246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.